Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Susan G who wrote (113702)	9/14/2000 4:12:31 PM
From: Gabriel	Read Replies (1) \| Respond to of 120523

susan hi-re:CEGE As previously reported, Cell Genesys ended the first quarter of 2000 with $250 million in cash, cash equivalents and short term investments derived primarily from the February 2000 sale of a portion of the company's holdings in Abgenix, Inc., a former subsidiary. The decrease in cash in the second quarter of 2000 was due principally to an estimated tax payment relating to the sale of Abgenix stock. Following the sale, Cell Genesys retains an approximately 12 percent interest or 9.7 million shares of Abgenix common stock